These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23980684)

  • 1. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
    Cardillo I; Spugnini EP; Galluzzo P; Contestabile M; Dell'Anna ML; Picardo M; Crispi S; Calogero RA; Piccolo MT; Arigoni M; Cantarella D; Boccellino M; Quagliuolo L; Ferretti G; Carlini P; Felici A; Boccardo F; Cognetti F; Baldi A
    Future Oncol; 2013 Sep; 9(9):1375-88. PubMed ID: 23980684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
    Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
    Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
    Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
    Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.
    Wu H; Xin Y; Zhao J; Sun D; Li W; Hu Y; Wang S
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):879-87. PubMed ID: 21290245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
    Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel.
    Li K; Mao Y; Lu L; Hu C; Wang D; Si-Tu J; Lu M; Peng S; Qiu J; Gao X
    Int J Oncol; 2016 Oct; 49(4):1679-85. PubMed ID: 27633058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
    Guérin O; Formento P; Lo Nigro C; Hofman P; Fischel JL; Etienne-Grimaldi MC; Merlano M; Ferrero JM; Milano G
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):51-7. PubMed ID: 17593391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100A3 suppression inhibits in vitro and in vivo tumor growth and invasion of human castration-resistant prostate cancer cells.
    Kang M; Lee HS; Lee YJ; Choi WS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Urology; 2015 Jan; 85(1):273.e9-15. PubMed ID: 25440760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N
    Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.